Enough is enough: targeted eculizumab withdrawal in atypical hemolytic uremic syndrome

Affiliations

¹ Department of Pediatric Nephrology, Amalia Children's Hospital, Radboud University Medical Center, Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands. Electronic address: Romy.Bouwmeester@radboudumc.nl.
² Department of Pediatric Nephrology, Amalia Children's Hospital, Radboud University Medical Center, Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands.
³ Department of Nephrology, Radboud University Medical Center, Radboud Institute of Health Sciences, Nijmegen, The Netherlands.

Free article

Comment

Romy N Bouwmeester et al. Kidney Int. 2021 Aug.

Free article

. 2021 Aug;100(2):265-268.

doi: 10.1016/j.kint.2021.02.033. Epub 2021 Mar 3.

¹ Department of Pediatric Nephrology, Amalia Children's Hospital, Radboud University Medical Center, Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands. Electronic address: Romy.Bouwmeester@radboudumc.nl.
² Department of Pediatric Nephrology, Amalia Children's Hospital, Radboud University Medical Center, Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands.
³ Department of Nephrology, Radboud University Medical Center, Radboud Institute of Health Sciences, Nijmegen, The Netherlands.

No abstract available

Keywords: TMA; aHUS; atypical hemolytic uremic syndrome; complement; eculizumab.

Comment on

Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study.
Fakhouri F, Fila M, Hummel A, Ribes D, Sellier-Leclerc AL, Ville S, Pouteil-Noble C, Coindre JP, Le Quintrec M, Rondeau E, Boyer O, Provôt F, Djeddi D, Hanf W, Delmas Y, Louillet F, Lahoche A, Favre G, Châtelet V, Launay EA, Presne C, Zaloszyc A, Caillard S, Bally S, Raimbourg Q, Tricot L, Mousson C, Le Thuaut A, Loirat C, Frémeaux-Bacchi V. Fakhouri F, et al. Blood. 2021 May 6;137(18):2438-2449. doi: 10.1182/blood.2020009280. Blood. 2021. PMID: 33270832 Clinical Trial.